Stada and Xbrane Get EU Approval for Lucentis Biosimilar for Eye Disease
The European Commission has granted a marketing authorization to Stada and Xbrane’s Ximluci (ranibizumab), a biosimilar of Novartis’ Lucentis (ranibizumab), to treat retinal vascular disorders....